Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (2020 - 2025)

Rani Therapeutics Holdings has reported Shares Outstanding over the past 6 years, most recently at $97.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $97.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $97.6 million (changed N/A YoY), and the annual figure for FY2025 was $97.6 million, changed.
  • Shares Outstanding for Q4 2025 was $97.6 million at Rani Therapeutics Holdings, up from $24.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for RANI hit a ceiling of $97.6 million in Q4 2025 and a floor of $19.7 million in Q3 2021.
  • Median Shares Outstanding over the past 5 years was $25.6 million (2023), compared with a mean of $32.5 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 57.96% in 2021 and later skyrocketed 60.84% in 2025.
  • Rani Therapeutics Holdings' Shares Outstanding stood at $19.7 million in 2021, then increased by 22.34% to $24.1 million in 2022, then grew by 7.96% to $26.0 million in 2023, then grew by 14.48% to $29.8 million in 2024, then surged by 227.51% to $97.6 million in 2025.
  • The last three reported values for Shares Outstanding were $97.6 million (Q4 2025), $47.9 million (Q3 2025), and $24.0 million (Q2 2025) per Business Quant data.